drugset / Trial / NCT07829874
Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the efficacy and safety of cryoablation combined with QL1706 (iparomlimab/tuvonralimab) plus lenvatinib in patients with advanced biliary tract cancer (BTC) who have progressed after first-line treatment.
Timeline
- Start
- 2026-09-20
- Primary completion
- 2028-09-20
- Completion
- 2029-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | — |
| Subject | QL1706 | Monoclonal antibody | — | — |